ERBB2 and breast carcinoma: Despite the discordance of HER2 negative primary tumors and HER2 positive CTC reported in breast cancer, in lung cancer, a recent study analyzed the PD-L1 expression on CTCs, cytology imprints and tissue samples of NSCLC patients.